BNP Paribas Asset Management
REVB icon

BNP Paribas Asset Management’s Revelation Biosciences REVB Stock Holding History

BNP Paribas Asset Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9 Hold
9
– – ﹤0.01% 2257
2026
Q1 		$11 Sell
9
-1
-10% -$2 ﹤0.01% 2258
2025
Q4 		$0 Buy
+10
New +$44 ﹤0.01% 2300

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

BNP Paribas Asset Management's REVB Position: Q2 2026 in Review

BNP Paribas Asset Management held its Revelation Biosciences (REVB) position steady in Q2 2026 at 9 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

BNP Paribas Asset Management first reported a position in REVB in Q4 2025 and has held it in 3 quarters since. The position peaked at $11 in Q1 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • BNP Paribas Asset Management held 9 shares of Revelation Biosciences worth $9 as of Q2 2026.
  • BNP Paribas Asset Management left its Revelation Biosciences share count unchanged in Q2 2026.
  • Revelation Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2257 holding.
  • BNP Paribas Asset Management first reported a position in Revelation Biosciences in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Revelation Biosciences position peaked at $11 in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.